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Abstract
Background: In practice, small bowel cancer is a rare entity. The most common histologic subtype is adenocarcinoma.
Adenocarcinoma of the small bowel (SBA) is challenging to diagnose, often presents at a late stage and has a poor
prognosis. The treatment of early-stage SBA is surgical resection. No standard protocol has been established for
unresectable or metastatic disease.
Case presentation: We report here on a 26-year-old man with SBA in the jejunum, lacking specific symptoms and
with a delay of 6 months in diagnosis. The diagnosis was finally achieved with a combination of balloon-assisted
enteroscopy, computed tomography scans, positron emission computed tomography scans and the values of
carcino-embryonic antigen and carbohydrate antigen 19-9. The patient underwent segmental intestine with lymph
node resection, followed by eight cycles of FOLFOX palliative chemotherapy with good tolerance. As of the 11-month
postoperative follow-up, there has been no evidence of recurrent disease.
Conclusions: This case is reported to arouse a clinical suspicion of SBA in patients with abdominal pain of unknown
cause. We also provided evidence in this case of a response to palliative chemotherapy with FOLFOX. Because the
incidence of SBA is very low, there is a need for further studies to evaluate the possible application of newer
investigative agents and strategies to obtain a better outcome within the framework of international collaborations.
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Background
Small bowel cancer is a rare malignancy that comprises
less than 5 % of all gastrointestinal malignancies. The es-
timated annual incidence is 0.3–2.0 cases per 100,000
persons, with a higher prevalence rates in the black
population than the white, and has been recently in-
creasing [1, 2]. It is most frequently diagnosed among
people aged 55–64, with the incidence increasing after
age 40. The current 5-year survival rate in the USA is
65.5 %; cancer stage at diagnosis has a strong influence
on the length of survival [3].
Small bowel cancer has four common histological types:
adenocarcinoma (30–40 %), carcinoid tumour (35–42 %),
lymphoma (15–20 %), and sarcoma (10–15 %) [4]. Adeno-
carcinoma of the small bowel (SBA) is most commonly
located in the duodenum (57 %), while 29 % of cases are
located in the jejunum and 10 % in the ileum [5]. Clinical
presentation of SBA is nonspecific abdominal discomfort,
such as abdominal pain, nausea, vomiting, gastrointestinal
bleeding and intestinal obstruction, which leads to an
average delay of 6–10 months in diagnosis [6]. Due to the
rarity of this cancer, there have been no good screening
methods developed for SBA; little is known about the clin-
ical characteristics, treatment modalities or prognosis of
patients with SBA, especially in Asians.
Here, we report on a 26-year-old man with SBA in the
jejunum, without specific symptoms. He was diagnosed
until he had an incomplete small bowel obstruction,
with a delay of 6 months in diagnosis. Segmental intes-
tine with lymph node resection was performed, followed
by eight cycles of FOLFOX palliative chemotherapy. The
patient was doing well as of his last follow-up.
Case presentation
The patient was male, 26 years old and had no specific
underlying or family disease. Six months ago, he experi-
enced an episodic attack of distending pain in his left
lower quadrant, nausea and vomiting; he was treated
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with oral drugs at a local hospital. However, his symptoms
were not completely relieved, and were later aggravated. A
normal abdominal X-ray suggested incomplete small
bowel obstruction. He was admitted to our hospital.
The patient visited our hospital without any complaints.
Physical examination revealed a soft abdomen with ten-
derness in the left lower quadrant. No mass was palpated
in the abdomen. When his abdominal pain occurred, a
peristaltic wave could be observed around the navel.
Laboratory tests showed no anaemia or leukocytosis.
Examination of tumour-associated antigens showed a
prominent high levels of carcino-embryonic antigen
(CEA) at 29.17 ng/ml and carbohydrate antigen 19-9 (CA
19-9) at 970.3 U/ml. Abdominal computed tomography
(CT) scans showed many swollen lymph nodes adjacent
to the abdominal aorta in the retroperitoneal space (Fig. 1)
but no discernible mass. Positron emission computed
tomography (PET)/CT scans revealed abnormal accumu-
lations of 18F-FDP in many stiffening intestinal segments
and also in many retroperitoneal swollen lymph nodes, in-
dicating hypermetabolism disease, with a high possibility
of a malignant disease (Fig. 2). Gastroscopy and entero-
scopy showed that the stomach, colon and rectum were
normal. However, double-balloon enteroscopy (DBE) and
the following biopsy revealed at the upper jejunum that
most of the lumen was obstructed by an irregular protru-
sive tumour of gastrointestinal origin (Fig. 3a).
Because of the symptoms of intestinal obstructions
and a high possibility of advanced stage, the patient
underwent segmental resection of the jejunum. At lapar-
otomy, a 5 × 5 cm round mass with no distinct boundary
was present at the jejunum (25 cm from the ligament of
Treitz). The mass involved the entire wall of the small
intestine and directly invaded the neighbouring mesen-
tery. There were many enlarged lymph nodes around the
superior mesenteric vein and the first and second jejunal
arteries in the involved mesentery. There was no evi-
dence of metastatic lesions in the peritoneum or liver
during intraoperative inspection of all quadrants of the
abdominal cavity. We performed a radical resection with
40 cm of the jejunum and the involved mesentery,
vessels and lymph nodes (Fig. 3b, c). Pathologic examin-
ation revealed a moderately differentiated adenocarcin-
oma with metastasis to seven out of 14 resected lymph
nodes (Fig. 4); free surgical margins were achieved. The
tumour was staged as T4N2M0, stage IIIB disease [7].
Genetic studies of the specimen revealed that it had low
expression of thymidylate synthase (TS) and excision re-
pair cross-complementing gene 1 (ERCC1), sensitive to
fluoropyrimidine and platinum [8]. He was started on
palliative chemotherapy with FOLFOX for a total of
eight cycles. He tolerated chemotherapy well, and the
values of CEA and CA 19-9 decreased gradually as the
chemotherapy progressed (Fig. 5a). CT scans also
showed that the swollen lymph nodes adjacent to the ab-
dominal aorta were significantly lessened (Fig. 5b). As of
the 11-month postoperative follow-up, there has been
no evidence of recurrent disease.
Discussion
Whereas the small bowel represents 75 % of the length
of the digestive tract and 90 % of the absorptive mucosal
surface area, tumour of the small bowel is rarer than
other gastrointestinal malignancies. The possible expla-
nations include the high levels of IgA and the more
rapid transit in the small bowel compared to the large
bowel. Little bacteria and more sensitivity to stress in
the small bowel also contribute to the low tumour inci-
dence [9]. Though small bowel cancer normally occurs
in elderly patients [3], in this case, it was found in a 26-
year-old young man. The mass remained undetectable
until he had an incomplete small bowel obstruction with
lymph node metastasis. This was similar with studies, in
which diagnosis of SBA was mainly obtained at
advanced stages; ~40 % of patients have lymph node me-
tastasis (stage III), and 35 to 40 % have distant metasta-
sis (stage IV) [6, 10].
The symptoms of SBA are initially nonspecific abdom-
inal discomfort; diagnosis is delayed and usually in the
context of emergency involving an occlusion (40 %) or
bleeding (24 %) [6], which is similar to the presentation
of our patient. For diagnosis of SBA, CT scans have an
overall accuracy rate of 47 % [11]. While CT scans can de-
tect the lesions, they cannot provide precise data of the in-
testinal mucosa and miss some small or flat lesions. The
PET/CT technique is being used to differentiate small in-
testinal malignant tumours from benign ones. The uptake
Fig. 1 CT scan image (axial view) showing many swollen lymph
nodes adjacent to the abdominal aorta in the retroperitoneal space
but no discernible mass
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Fig. 2 PET/CT scan image showing abnormal accumulations of 18F-FDP in many intestinal segments and also in many retroperitoneal swollen
lymph nodes, indicating hypermetabolism disease, with a high possibility of a malignant disease
Fig. 3 a DBE examination showing at the upper jejunum; lumen was narrowed by an irregular protrusive tumour. b About 40 cm of the involved
jejunum, mesentery and vessels were resected. c Tumour involved the entire wall of the small intestine
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of 18F-FDG is related to tumour size, infiltration and
lymph node metastasis; the higher the uptake of 18F-FDG,
the higher the tumour invasiveness [12]. Gastroscopy and
enteroscopy can be appropriate if the tumour is located
close to the proximal duodenum or far from the terminal
ileum. The rest of the small bowel cannot be accessed
without the use of video capsule endoscopy (CE) or DBE.
The definite diagnostic yield of CE is only 20–30 %, while
DBE accounts for 60–70 % of the diagnostic yield for in-
testinal diseases [13]. However, CE is suitable for diagnos-
ing scattered, small and multiple lesions, as well as active
bleeding; it is convenient, non-invasive, secure and com-
fortable. In contrast, the DBE procedure is uncomfortable,
less tolerated and difficult to complete; these factors influ-
ence its diagnosis [13]. A baseline plasmatic CEA and CA
19-9 assay is necessary, especially in cases of advanced dis-
ease because CEA and CA 19-9 levels are of prognostic
value [14]. In this case, the diagnosis was achieved by the
combination of the DBE results, CT images, PET/CT im-
ages and the values of CEA and CA 19-9.
Surgical resection with clear margins and regional
lymph node resection remains the treatment of choice in
localized SBA; indeed, it is often required even in meta-
static SBA due to the high probability of obstruction or
severe haemorrhage [15]. To date, there has been no
standard chemotherapy regimen against SBA. Several
studies have explored the role of palliative chemotherapy
in advanced SBA. Hong et al. [16] have shown in stage
IV patients who received palliative chemotherapy that
overall survival (OS) increased significantly compared to
those who did not receive chemotherapy (8 vs. 3 months,
p = 0.025). Ecker et al. [17] have shown that median OS
was superior for patients with resected stage III SBA
who were receiving chemotherapy versus those who
were not (42.4 vs 26.1 months, p < 0.001). As for the
Asian population, Mizyshima et al. [18] showed that, in
patients with non-curative resection or unresectable dis-
tant metastasis, the response rate to chemotherapy was
31.6 %, and the 3-year OS rate was significantly higher
compared to the response rate without chemotherapy
(26.3 vs. 13.8 %; p = 0.008). Several chemotherapy drugs
have also been evaluated in the treatment of metastatic
SBA. Zaanan et al. [14] have shown that the median OS
in advanced SBA patients treated with FOLFOX was
Fig. 4 Microscopic images of the tumour from the pathologic specimen; haematoxylin and eosin staining. a Low-power magnification (×100)
showing a moderately differentiated adenocarcinoma of the jejunum with invasion into the lymph nodes. b High-power magnification (×400)
showing adenocarcinoma
Fig. 5 a Values of CEA (left Y-axis) and CA 19-9 (right Y-axis) decreased gradually as the eight cycles of FOLFOX palliative chemotherapy
progressed. b CT scan image (axial view) showing swollen lymph nodes adjacent to the abdominal aorta in the retroperitoneal space lessened
after chemotherapy
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17.8 months, the longest survival among different
chemotherapy regimens. Two phase II studies have been
conducted to evaluate the efficacy of different chemo-
therapy regimens in advanced SBA: the response rates
were around 50 %, the median progression-free survivals
7.8 and 11.3 months and the median OS 15.2 and
20.4 months [19, 20]. Newer agents, such as endothelial
growth receptor (EGFR) antibody drugs, and newer
combinations are being explored as the second line for
improved treatment of advanced SBA [21]. From limited
clinical reports, a combination of fluoropyrimidine with
platinum compounds (FOLFOX or CAPOX) has been
proposed as the first-line treatment for palliative chemo-
therapy in metastatic SBA treatment [22]. In view of the
results of genetic studies, the patient underwent pallia-
tive chemotherapy for eight cycles of FOLFOX and was
doing well as of his last follow-up.
Conclusions
We report a rare case of jejunum adenocarcinoma in a
young man in China. Diagnosis of SBA remains a chal-
lenge. A physician’s suspicion and awareness is crucial in
patients with abdominal pain of unknown cause.
Patients with delayed diagnosis often have a poorer
prognosis. Surgery remains the primary treatment. In
this case, we noticed a response to palliative chemother-
apy with FOLFOX. Because the incidence of SBA is very
low, there is a need for further studies to evaluate the
possible application of newer investigative agents and
strategies to obtain a better outcome within the frame-
work of international collaborations.
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